Single-batch production of recombinant human polyclonal antibodies.

ABSTRACT: We have previously described the development and implementation of a strategy for production of recombinant polyclonal antibodies (rpAb) in single batches employing CHO cells generated by site-specific integration, the Sympress I technology. The Sympress I technology is implemented at industrial scale, supporting a phase II clinical development program. Production of recombinant proteins by site-specific integration, which is based on incorporation of a single copy of the gene of interest, makes the Sympress I technology best suited to support niche indications. To improve titers while maintaining a cost-efficient, highly reproducible single-batch manufacturing mode, we have evaluated a number of different approaches. The most successful results were obtained using random integration in a

SUBMITTER: Nielsen LS 

PROVIDER: S-EPMC2881207 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature